Cytochrome p450-dependent disposition of the enantiomers of citalopram and its metabolites: In vivo studies in Sprague-Dawley and Dark Agouti rats

Chirality

Volumn 23, Issue 2, 2011, Pages 172-177

  Kingbäck, Maria ^a   Carlsson, Björn ^a   Ahlner, Johan ^a,b   Bengtsson, Finn ^a   Kugelberg, Fredrik C ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b National Board of Forensic Medicine   (Sweden)

Author keywords

citalopram; CYP2D6; Dark Agouti; enantiomer; pharmacokinetics; Sprague Dawley

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2D6; DEMETHYLCITALOPRAM; DIDEMETHYLCITALOPRAM; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DARK AGOUTI RAT; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; ENANTIOMER; ENZYME DEFICIENCY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; NONHUMAN; OSMOTIC PUMP; PHARMACOGENETICS; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STRAIN DIFFERENCE;

ANIMALS; CEREBRAL CORTEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITALOPRAM; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; INFUSION PUMPS, IMPLANTABLE; MESENCEPHALON; MODELS, ANIMAL; PHENOTYPE; RATS; RATS, INBRED STRAINS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; SPECIES SPECIFICITY; STEREOISOMERISM;

EID: 78650947202     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20901     Document Type: Article

References (40)

1. Andrews JM, Nemeroff CB,. Contemporary management of depression. Am J Med 1994; 97: 24S-32S.
2. Hyttel J, Bøgesø KP, Perregaard J, Sánchez C,. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992; 88: 157-160.
3. Owens MJ, Knight DL, Nemeroff CB,. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345-350.
4. Øyehaug E, Østensen ET, Salvesen B,. High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr 1984; 308: 199-208.
5. Sindrup SH, Brøsen K, Hansen MG, Aaes-Jørgensen T, Overø KF, Gram LF,. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 15: 11-17.
6. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K,. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73-78.
7. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y,. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997; 280: 927-933.
8. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS, Shader RI,. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999; 46: 839-849.
9. Olesen OV, Linnet K,. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 1999; 59: 298-309.
10. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI,. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29: 1102-1109.
11. Herrlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson LL, Bertilsson L,. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 2003; 56: 415-421.
12. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA,. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442-446.
13. Al-Dabbagh SG, Idle JR, Smith RL,. Animal modelling of human polymorphic drug oxidation-the metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol 1981; 33: 161-164.
14. Gonzalez FJ, Matsunaga T, Nagata K, Meyer UA, Nebert DW, Pastewka J, Kozak CA, Gillette J, Gelboin HV, Hardwick JP,. Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 1987; 6: 149-161.
15. Schulz-Utermoehl T, Bennett AJ, Ellis SW, Tucker GT, Boobis AR, Edwards RJ,. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 1999; 9: 357-366.
16. Matsunaga E, Gonzalez FJ,. Specific cytosine demethylations within the first exons of the rat CYP2D3 and CYP2D5 genes are associated with activation of hepatic gene expression during development. DNA Cell Biol 1990; 9: 443-452.
17. Barham HM, Lennard MS, Tucker GT,. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochem Pharmacol 1994; 47: 1295-1307.
18. Miksys S, Rao Y, Sellers EM, Kwan M, Mendis D, Tyndale RF,. Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica 2000; 30: 547-564.
19. Wikell C, Apelqvist G, Carlsson B, Hjorth S, Bergqvist PBF, Kugelberg FC, Ahlner J, Bengtsson F,. Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats. Clin Neuropharmacol 1999; 22: 327-336.
20. Cremers TIFH, de Boer P, Liao Y, Bosker FJ, den Boer JA, Westerink BHC, Wikström HV,. Augmentation with a 5-HT(1A), but not a 5-HT(1B) receptor antagonist critically depends on the dose of citalopram. Eur J Pharmacol 2000; 397: 63-74.
21. Kugelberg FC, Apelqvist G, Carlsson B, Ahlner J, Bengtsson F,. In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats. Br J Pharmacol 2001; 132: 683-1690.
22. Wegener G, Bandpey Z, Heiberg IL, Mørk A, Rosenberg R,. Increased extracellular serotonin level in rat hippocampus induced by chronic citalopram is augmented by subchronic lithium: neurochemical and behavioural studies in the rat. Psychopharmacology (Berl) 2003; 66: 188-194.
23. Kugelberg FC, Apelqvist G, Carlsson B, Ahlner J, Bengtsson F,. Sustained citalopram treatment in experimental hepatic encephalopathy: effects on entrainment to the light-dark cycle and melatonin. Basic Clin Pharmacol Toxicol 2006; 99: 80-88.
24. Rochat B, Amey M, Baumann P,. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 1995; 17: 273-279.
25. Carlsson B, Olsson G, Reis M, WÃlinder J, Nordin C, Lundmark J, Scordo MG, Dahl ML, Bengtsson F, Ahlner J,. Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monit 2001; 23: 658-664.
26. Kugelberg FC, Apelqvist G, Bengtsson F,. Effects of chronic citalopram treatment on central and peripheral spontaneous open-field behaviours in rats. Pharmacol Toxicol 2002; 90: 303-310.
27. Mørk A, Kreilgaard M, Sánchez C,. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003; 45: 67-173.
28. Sánchez C, Gruca P, Bien E, Papp M,. R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav 2003; 75: 903-907. (Pubitemid 37289476)
29. Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C,. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004; 174: 163-176.
30. Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sánchez C, Haddjeri N,. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int J Neuropsychopharmacol 2006; 1: 1-10.
31. Mnie-Filali O, Faure C, Mansari ME, Lambas-Senas L, Berod A, Zimmer L, Sánchez C, Haddjeri N,. R-citalopram prevents the neuronal adaptive changes induced by escitalopram. Neuroreport 2007; 18: 1553-1556.
32. Baumann P, Eap CB,. Enantiomeric antidepressant drugs should be considered on individual merit. Hum Psychopharmacol 2001; 16: S85-S92.
33. Kugelberg FC, Carlsson B, Ahlner J, Bengtsson F,. Stereoselective single-dose kinetics of citalopram and its metabolites in rats. Chirality 2003; 15: 622-629.
34. Fredricson Overø K,. The pharmacokinetic and safety evaluation of citalopram from preclinical and clinical data. In:, Montgomery SA, editor. XXII Nordiske Psykiater-kongres. Reykjavik: Excerpta Medica; 1989. p 22-30.
35. Miksys SL, Tyndale R.F., Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 2002; 27: 406-415.
36. Hedlund E, Gustafsson JÅ, Warner M,. Cytochrome P450 in the brain; a review. Curr Drug Metab 2001; 2: 245-263.
37. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, Eap CB, Baumann P,. Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 2000; 855: 235-243.
38. Gervasini G, Carrillo JA, Benitez J,. Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin Pharmacokinet 2004; 43: 693-706.
39. Kosel M, Gnerre C, Voirol P, Amey M, Rochat B, Bouras C, Testa B, Baumann P,. In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations. Mol Psychiatry 2002; 7: 181-188.
40. Uhr M, Grauer MT,. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 2003; 37: 179-185.